Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.
Zhejiang Hisun Pharmaceutical Co Total Equity Related Terms
Zhejiang Hisun Pharmaceutical Co Total Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Hisun Pharmaceutical Co Total Equity Chart
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang Hisun Pharmaceutical Co (SHSE:600267) has a Total Equity of ¥9,195 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Zhejiang Hisun Pharmaceutical Co and its competitors.
Is Zhejiang Hisun Pharmaceutical Co's Total Equity too high?
Zhejiang Hisun Pharmaceutical Co's current Total Equity is ¥9,195 Mil. Overall, Zhejiang Hisun Pharmaceutical Co has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Hisun Pharmaceutical Co's Total Equity compare to ZTS?
Zhejiang Hisun Pharmaceutical Co's Total Equity of ¥9,195 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Zhejiang Hisun Pharmaceutical Co and its competitors. Zhejiang Hisun Pharmaceutical Co's current Total Equity is ¥9,195 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Hisun Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Hisun Pharmaceutical Co (SHSE:600267) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥8.86, compared to a current price of ¥11.75 — trading 32.6% above its estimated fair value. The current Total Equity is ¥9,195 Mil. Zhejiang Hisun Pharmaceutical Co's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Zhejiang Hisun Pharmaceutical Co (SHSE:600267), the current Total Equity is ¥9,195 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Hisun Pharmaceutical Co (SHSE:600267) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Hisun Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥11.75 is trading 32.6% above its estimated GF Value™ of ¥8.86.
GuruFocus considers Zhejiang Hisun Pharmaceutical Co to be Significantly Overvalued.
Key valuation signals for SHSE:600267:
Total Equity: ¥9,195 Mil
GF Value™: ¥8.86 vs. price of ¥11.75 (32.6% above fair value)
No single metric tells the full story. See the SHSE:600267 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Hisun Pharmaceutical Co Business Description
Zhejiang Hisun Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is focused on the research, development, and distribution of pharmaceuticals. It produces and supplies antibiotics and anticancer drugs. The company's research channels cover indications like anticancer, cardiovascular, anti-infective, anti-parasitic, immunosuppressant and others. Its product portfolio includes active pharmaceutical ingredients like Anastrozole, Docetaxel, Methotrexate, and others and finished dosages such as letrozole tablets, anastrozole tablets, injection mitomycin, and others.
58GF Score
Get the complete analysis for SHSE:600267
Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600267 has been successfully added to your 
